In 2015, an expert group met for a consensus agreement and agreed that a single international classification scheme is needed to enable communication with patients and physicians [2]. The lack of classification criteria led to heterogeneity in observational and interventional research efforts, stated Prof. Joseph F. Merola (Brigham and Women´s Hospital, Harvard Medical School, USA). Particularly striking was the absence of classification criteria for discoid lupus erythematosus (DLE), the most common type of CLE. Therefore, a list of 12 potential clinical and histopathologic items to serve as classification criteria of DLE was developed in 2017 (see Figure) [3]. “This effort represented a key step towards the development of formal DLE classification criteria,” concluded Prof. Merola.
Figure: Potential classification criteria of discoid lupus erythematosus. Modified from [3]
- Merola JF. 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
- Merola JF, et al. Lupus Sci Med 2015;2:e000085.
- Elman SA, et al. J Am Acad Dermatol 2017: 77:261-267.
Posted on
Previous Article
« Skin toxicity of immune checkpoint inhibitors Next Article
Biologicals beyond TNF blockade »
« Skin toxicity of immune checkpoint inhibitors Next Article
Biologicals beyond TNF blockade »
Table of Contents: WCD 2019
Featured articles
Letter from the Editor
Insights into pathogenesis of AD define novel therapeutic targets
Treating Psoriasis in 2019
Choosing the right biologic in psoriasis
Registries – an important research tool in biologics
Atopic Dermatitis – What is New
Insights into pathogenesis of AD define novel therapeutic targets
Combinations are hot in AD treatment
Dermal Reactions to Systemic Drugs
Cutaneous adverse events due to EGFR inhibitors
Management strategies for drug-induced mucositis
Skin toxicity of immune checkpoint inhibitors
Lupus Erythematosus Today
New targets and biologics for cutaneous lupus erythematosus
Novel lupus classification will aid future research
Hidradenitis Suppurativa
Various guidelines with much overlap
Antibiotics in hidradenitis suppurativa
Biologicals beyond TNF blockade
Small Molecules – What to Expect
Novel treatment options for many dermatologic indications
Long awaited oral therapy for moderate-to-severe AD
Novel treatment options in alopecia areata and vitiligo
Optimising the Management of Keloids
Keloids: a faulty switch in wound healing?
What the future of keloid treatment could hold
Malignant Melanoma – Advances in Management
Will malignant melanoma become a curable disease?
Best of the Posters
Related Articles
September 17, 2021
Unresolved needs for patients with PsA despite growing therapeutic options
September 17, 2021
COVID-19 affects patients and care
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy